FDA Allows Human Trials of Aptose’s CG-806 Oral Compound for AML
News
The U.S. Food and Drug Administration (FDA) has granted Aptose Biosciences an investigational new drug (IND) allowance that will let the company begin a human Phase 1a/b clinical study of ... Read more